DUBLIN--(BUSINESS WIRE)--The "Antiplatelet Market: Analysis By Drug Class, By Route of Administration, By Distribution Channel, By Region Size and Trends" report has been added to ...
Patients who received a single antiplatelet drug therapy— usually aspirin — after transcatheter aortic valve replacement (TAVR) had about half the risk of dying in the subsequent 6 months compared ...
PhaseBio Pharmaceuticals, Inc. PHAS reported interim data from the ongoing phase III REVERSE-IT study evaluating its lead product candidate bentracimab to reverse the antiplatelet effects of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback